Imagenebio Inc (IMA)

$5.70 -0.02 (-0.44%)
Market Cap 59.77M
Revenue (ttm) 800,000.00
Net Income (ttm) -45.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,668.75%
Debt to Equity Ratio 0.00
Volume 266,912
Avg Vol 431,086
Day's Range N/A - N/A
Shares Out 10.65M
Stochastic %K 56%
Beta 0.73
Analysts Sell
Price Target $13.00

Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, In...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 345 6265
Address:
12526 High Bluff Drive, Suite 345, San Diego, United States
BecauseOfScout
BecauseOfScout Apr. 30 at 4:41 PM
$IMA Can’t ignore the 18m vol hammer candle. Small stater started.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 18 at 3:04 AM
$IMA RSI: 64.71, MACD: -0.0707 Vol: 0.46, MA20: 5.27, MA50: 5.98 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jcod21
Jcod21 Apr. 16 at 5:44 PM
$IMA low volume day and hanging in there like a champ. Just a pinch of news or gossip and this can find its way 6+. Hang in there longs. The day will come.
0 · Reply
luckysupernova
luckysupernova Apr. 15 at 8:13 PM
$IMA so why do they sell ah below the closing price each day. Thats odd to lose money ah or are they shorting ah everyday lol
0 · Reply
permabull869
permabull869 Apr. 15 at 11:38 AM
$IMA 6+ today?
0 · Reply
Prolmt85
Prolmt85 Apr. 14 at 4:04 PM
$IMA come on baby 💰
0 · Reply
Santa34
Santa34 Apr. 14 at 4:03 PM
$IMA almost green 🟢🔥
0 · Reply
Papakush5005
Papakush5005 Apr. 14 at 2:29 PM
$IMA here we go!
0 · Reply
Mad36
Mad36 Apr. 14 at 1:27 PM
$IMA might be a rebound day
0 · Reply
Jimmytrader35
Jimmytrader35 Apr. 14 at 9:29 AM
$IMA Glad I sold yesterday at 5.60 jheez
0 · Reply
Latest News on IMA
ImageneBio price target lowered to $24 from $30 at Leerink

2026-05-08T10:12:52.000Z - 5 days ago

ImageneBio price target lowered to $24 from $30 at Leerink

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

May 7, 2026, 4:05 PM EDT - 5 days ago

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

ImageneBio Announces $30 Million Private Placement

Apr 13, 2026, 7:00 AM EDT - 4 weeks ago

ImageneBio Announces $30 Million Private Placement

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026, 4:30 PM EDT - 2 months ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Mar 10, 2026, 8:00 AM EDT - 2 months ago

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

ImageneBio to Participate in Leerink Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

ImageneBio to Participate in Leerink Global Healthcare Conference

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Feb 10, 2026, 7:00 AM EST - 3 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

MLTX

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

Nov 12, 2025, 7:15 AM EST - 6 months ago

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Nov 6, 2025, 8:30 AM EST - 6 months ago

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Jul 25, 2025, 11:00 AM EDT - 10 months ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Jul 23, 2025, 9:00 AM EDT - 10 months ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

PSTX

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Jul 15, 2025, 4:15 PM EDT - 10 months ago

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Jul 11, 2025, 8:00 AM EDT - 10 months ago

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Dec 23, 2024, 8:37 AM EST - 1 year ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Ikena Oncology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

Ikena Oncology Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Reports Second Quarter 2024 Financial Results

UPDATE – Ikena Oncology Announces Strategic Update

May 28, 2024, 4:42 PM EDT - 2 years ago

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology Announces Strategic Update

May 28, 2024, 4:15 PM EDT - 2 years ago

Ikena Oncology Announces Strategic Update

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

May 13, 2024, 4:45 PM EDT - 2 years ago

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Feb 21, 2024, 4:15 PM EST - 2 years ago

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Jan 18, 2024, 4:05 PM EST - 2 years ago

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Nov 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Ikena Oncology to Participate in September 2023 Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in September 2023 Investor Conferences

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology to Participate in Upcoming Investor Conferences

May 24, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in Upcoming Investor Conferences

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

May 15, 2023, 7:50 AM EDT - 3 years ago

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Ikena Oncology Announces $40 Million Underwritten Offering

May 15, 2023, 7:45 AM EDT - 3 years ago

Ikena Oncology Announces $40 Million Underwritten Offering

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Apr 17, 2023, 9:00 AM EDT - 3 years ago

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Mar 7, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Mar 6, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Feb 28, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Ikena Oncology Appoints Owen Hughes as Board Chair

Dec 19, 2022, 4:30 PM EST - 3 years ago

Ikena Oncology Appoints Owen Hughes as Board Chair

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Nov 28, 2022, 8:00 AM EST - 3 years ago

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 7:30 AM EST - 3 years ago

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Nov 10, 2022, 9:00 AM EST - 3 years ago

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:48 AM EST - 3 years ago

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:05 AM EST - 3 years ago

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Oct 18, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Ikena Oncology to Participate in September 2022 Investor Conferences

Sep 6, 2022, 7:30 AM EDT - 4 years ago

Ikena Oncology to Participate in September 2022 Investor Conferences

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 11, 2022, 7:30 AM EDT - 4 years ago

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Jul 6, 2022, 7:00 AM EDT - 4 years ago

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BecauseOfScout
BecauseOfScout Apr. 30 at 4:41 PM
$IMA Can’t ignore the 18m vol hammer candle. Small stater started.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 18 at 3:04 AM
$IMA RSI: 64.71, MACD: -0.0707 Vol: 0.46, MA20: 5.27, MA50: 5.98 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jcod21
Jcod21 Apr. 16 at 5:44 PM
$IMA low volume day and hanging in there like a champ. Just a pinch of news or gossip and this can find its way 6+. Hang in there longs. The day will come.
0 · Reply
luckysupernova
luckysupernova Apr. 15 at 8:13 PM
$IMA so why do they sell ah below the closing price each day. Thats odd to lose money ah or are they shorting ah everyday lol
0 · Reply
permabull869
permabull869 Apr. 15 at 11:38 AM
$IMA 6+ today?
0 · Reply
Prolmt85
Prolmt85 Apr. 14 at 4:04 PM
$IMA come on baby 💰
0 · Reply
Santa34
Santa34 Apr. 14 at 4:03 PM
$IMA almost green 🟢🔥
0 · Reply
Papakush5005
Papakush5005 Apr. 14 at 2:29 PM
$IMA here we go!
0 · Reply
Mad36
Mad36 Apr. 14 at 1:27 PM
$IMA might be a rebound day
0 · Reply
Jimmytrader35
Jimmytrader35 Apr. 14 at 9:29 AM
$IMA Glad I sold yesterday at 5.60 jheez
0 · Reply
TurdSniper
TurdSniper Apr. 14 at 1:18 AM
$IMA Nice drop on this turd ⬇💩
0 · Reply
BearTamerTrading
BearTamerTrading Apr. 14 at 12:23 AM
Top stocks alerted & traded today 👇🏾 $RMSG $SANA $SKYQ $HOTH $IMA Plenty more was captured as well. Congratulations to all members and our fellow retail traders who tapped in today. Here is the replay for proof 👇🏾 My own results are in the comments for the stocks I remembered to snapshot 😅 https://www.youtube.com/live/yN2-sppreac?si=27QuZUyR_qSEtUns
2 · Reply
only1mc
only1mc Apr. 14 at 12:02 AM
$RMSG was a great day. made out on $IMA and $SKYQ sky rizzi. nothing like RmSG. Still holding onto $AIXI Accumulating many shares fur the run to come. ready for tomorrow
0 · Reply
Candyman_Trader
Candyman_Trader Apr. 13 at 10:53 PM
Trading “in the zone” paid off today. The only rule I broke is not going live for the $RMSG trade at EOD… sold all at 2.73 and ran from my station afterwards 😮‍💨. coulda, shoulda, woulda… 🤷‍♀️ was up 5.9% this morning and finishing account UP 23.4% TODAY! ✅ on $RMSG $RECT $IMA 🛑 on $ARAI $ALMU and$CMCT
0 · Reply
Santa34
Santa34 Apr. 13 at 10:38 PM
$IMA add more 👍
0 · Reply
Trader1141
Trader1141 Apr. 13 at 10:19 PM
$IMA had news and ended up with 14% gain $RMSG (garbage) no news and ednded up 600%+ Lol….. this stock market is a Casino… forget news, technicals, setups…. Just guess and you might catch a runner 🤣🤣
1 · Reply
defineme44
defineme44 Apr. 13 at 8:57 PM
$IMA i added thank you
0 · Reply
heydude84
heydude84 Apr. 13 at 8:30 PM
$IMA So what's with the huge drop AH? Is there any volume to it or just smoke and mirrors?
0 · Reply
topstockalerts
topstockalerts Apr. 13 at 8:24 PM
$IMA something feels different about this push… a lot more conviction behind it
0 · Reply
Jimmytrader35
Jimmytrader35 Apr. 13 at 8:20 PM
$IMA retard
1 · Reply
Jimmytrader35
Jimmytrader35 Apr. 13 at 8:19 PM
$IMA private placement you
0 · Reply
luckysupernova
luckysupernova Apr. 13 at 8:18 PM
$IMA has offering news, shouldnt be bullish at all
1 · Reply